Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMARANTH: AZD3293 in Early Alzheimer's Disease
jRCT2080222853Phase 3
- Sponsor
- AstraZeneca
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lanabecestat in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (3 arms), sponsored by AstraZeneca.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080222853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222853.